DSIP has no validated dosing protocol and no regulatory approval anywhere for any indication, so the honest answer to how it is dosed is that the published record documents a handful of decades-old experiments rather than a regimen. Human studies gave the peptide parenterally, most often by slow intravenous infusion, at doses expressed in nanomoles per kilogram, and the clinical work stopped rather than converging on a standard. The distance between that thin historical record and the vials sold through research-chemical channels today is the whole of the matter, because the material in those vials does not meet the pharmaceutical requirements the trial peptide did.
DSIP holds no regulatory approval in any jurisdiction and no validated dosing protocol, and the human literature that does exist rests on a small set of mostly European studies from the late 1970s through the late 1980s that most often infused 25 nanomoles per kilogram intravenously.
Every human study of DSIP that reported a route used a parenteral one, and the reason is structural rather than a matter of preference: a nine-amino-acid chain with no protection against gastric and intestinal proteases has no meaningful oral bioavailability, and no oral formulation was developed for the trials. The route list widens only in the animal work, and it widens into territory that does not transfer, which is why a DSIP dose figure encountered out of context may belong to an experiment that has no human counterpart at all.
Every published human DSIP study that reported a route used a parenteral one, with slow intravenous infusion dominating, because the nonapeptide is cleaved by digestive proteases and has no meaningful oral bioavailability.
The number that recurs through the human literature is 25 nanomoles per kilogram given intravenously, appearing across studies with aims as different as chronic insomnia and opiate and alcohol withdrawal. Recurrence is not validation. No dose-ranging program tested a ladder of doses against a measured endpoint to find an optimum; the figure appears to have been settled early from animal work and plausibility, then carried forward by later investigators as a convention, which is what a reader is actually looking at when the number is presented today as though it were a dose.
The 25 nanomoles per kilogram figure that recurs across the human DSIP literature converts to roughly 1.5 milligrams for a 70-kilogram adult at the peptide's molecular weight near 849 daltons, and it was never established through a dose-ranging program.
A dosing protocol is not a number someone published; it is the output of a defined regulatory process, and DSIP entered none of it. No medicines regulator anywhere has approved the peptide for any indication, in any formulation, at any dose, which is why the phrase does not really apply to it.
No medicines regulator in any jurisdiction has approved DSIP for any indication, in any formulation, at any dose, and the peptide holds no marketing authorization, no pharmacopeia listing, and no status as an approved compounding ingredient.
The reassuring-sounding line about DSIP is that serious acute reactions were not prominently reported in the trials. That statement is far weaker than it sounds: a few dozen participants, dosed over days rather than months and monitored for a handful of endpoints, can reveal a common and obvious harm and nothing else. An adverse effect striking one recipient in a hundred, or emerging only after months of exposure, would be entirely invisible to an evidence base that size.
DSIP's safety record consists of a small number of people dosed over days in short studies decades ago, which establishes nothing about repeated or long-term administration, drug interactions, or effects in pregnancy, adolescence, older adults, or anyone with liver, kidney, or psychiatric disease.
A plasma half-life measured in minutes sits at the center of the DSIP administration puzzle, because aminopeptidases and other serum and tissue proteases cleave a small unprotected peptide almost as quickly as it enters circulation. What the investigators reported did not match that arithmetic, and the mismatch is a large part of why the dosing question was never settled.
| Property | A minutes-long half-life predicts | The studies reported |
|---|---|---|
| Onset | Effects within the hour | Slow onset, often not on the dosing night |
| Duration | Ends with plasma clearance | Apparent persistence for days |
| Route choice | Bolus sufficient | Infusion used to hold a plasma level |
| Central exposure | Arrival scaled to dose | Non-saturable diffusion both ways, delivered fraction unresolved |
DSIP clears from plasma with a half-life measured in minutes, yet DSIP-like immunoreactivity is present endogenously at picomolar concentrations, so an administered dose sits orders of magnitude above baseline and leaves it unresolved whether the trials studied a physiological signal or pharmacologically overrode one.
Study design split along the line of what was being investigated, and the two branches of the literature barely resemble each other. The insomnia work dosed in the evening ahead of a recorded sleep period; the withdrawal work dosed across a block of days during acute withdrawal and scored symptoms rather than brain waves. Both branches built a gap between administration and measurement, and that gap, which the delayed-effect hypothesis made necessary, is exactly what makes the results hard to read.
| Design element | Insomnia studies | Withdrawal studies |
|---|---|---|
| Timing | Evening, ahead of the recorded sleep period | Across the acute withdrawal period |
| Repetition | Often consecutive nights | A block of consecutive days |
| Endpoint | Polysomnography | Symptom-severity scoring |
The insomnia protocols dosed in the evening across consecutive nights and recorded sleep for nights afterward because reported changes did not reliably appear on the night of the dose itself, and rigor across the literature ranged from double-blind and placebo-controlled work to open-label reports and essentially uncontrolled early observations.
A dose-response curve exists only where the dose was varied and the effect was watched to move, and the DSIP literature never did that in any systematic way. Most human studies ran a single dose level, so there was nothing to plot, and the animal work that did vary dose reported a shape that leaves any single tested dose uninterpretable without its neighbors.
Most human DSIP studies tested a single dose level with samples in the range of ten to thirty participants, so no dose-response curve was ever plotted, and the animal work that did vary dose frequently reported a biphasic, bell-shaped pattern rather than a clean rising line.
Research DSIP was supplied as a lyophilized powder because water is the medium in which peptides fall apart. Degraded peptide is not simply weaker peptide; the breakdown products are different molecules that may do nothing or may do something unintended, so a solution that has stood too long delivers an unknown quantity of an uncertain mixture. That is why two trials citing the same nanomolar figure may not have delivered the same amount of intact peptide, which makes study-to-study dose comparison shakier than the matching numbers suggest.
Research DSIP was supplied as a lyophilized powder because the sequence carries a mid-chain aspartate residue prone to isomerization and backbone cleavage and an amino-terminal tryptophan vulnerable to oxidation, and material used in human trials had to meet pharmaceutical requirements for verified identity, purity, sterility, and endotoxin control.
Rabbits and rats carry most of the DSIP animal literature, with the original isolation work done in rabbits and much of the later behavioral and electrophysiological work in rodents. Its real contribution was existence rather than dosing: it indicated the peptide had measurable central effects in some preparations under some conditions, and even that much was contested.
The DSIP animal literature rests mainly on rabbits and rats and includes intracerebroventricular and intracisternal routes that bypass the blood-brain barrier, so its doses cannot be converted to human ones by body weight or any fixed ratio, and several groups reported difficulty reproducing the sleep-promoting findings.
Educational use only. This article describes what the published scientific and clinical literature reports about DSIP. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
